ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VYGR vs BDTX // EV/EBITDA & P/E VALUATION

Voyager Therapeutics Inc. (NASDAQ) VS. Black Diamond Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: VYGR 1 — BDTX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VYGR VS. BDTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VYGR BDTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 10.80% -45.80 BDTX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 6.9x — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -49.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 5/9 -4.00 BDTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 31.8 45.4 -13.58 BDTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $108.4M $106.9M $1.6M VYGR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VYGR REV BDTX REV VYGR GROSS % BDTX GROSS % VYGR FCF BDTX FCF
FY 2025 $40.4M $0 — — -$135.1M $29.6M
FY 2024 $80.0M $0 — — -$18.8M -$62.3M
FY 2023 $250.0M $0 — — $77.9M -$66.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VYGR // BETA —
BDTX // BETA —